Drugs / 99mTc-HE3-G3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04277338 | Feb 2020 → Feb 2021 | breast cancer | Tomsk National Research Medical Center of the Russian Academy of Sciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 99mTc-HE3-G3 | “One single injection of 99mTc-HE3-G3, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.” NCT04277338 ↗ |
| Modality | Protein / enzyme biologic | “DARPin (designed ankyrin repeat proteins) G3 is a small (molecular weight, 14 kDa) scaffold protein with picomolar affinity to HER2.” PMID 34385343 ↗ Aug 2021 |
| Route | Intravenous | “after single intravenous injection” NCT04277338 ↗ |